Ameriprise Financial Inc. cut its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 19.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,281 shares of the biopharmaceutical company’s stock after selling 8,110 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.15% of Esperion Therapeutics worth $1,587,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in shares of Esperion Therapeutics by 29.4% in the 1st quarter. Bank of New York Mellon Corp now owns 104,603 shares of the biopharmaceutical company’s stock worth $3,693,000 after buying an additional 23,740 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Esperion Therapeutics by 174.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 110,475 shares of the biopharmaceutical company’s stock worth $3,901,000 after buying an additional 70,255 shares during the period. Meditor Group Ltd purchased a new stake in shares of Esperion Therapeutics in the 2nd quarter worth about $26,194,000. Swiss National Bank grew its position in shares of Esperion Therapeutics by 18.5% in the 2nd quarter. Swiss National Bank now owns 26,300 shares of the biopharmaceutical company’s stock worth $1,217,000 after buying an additional 4,100 shares during the period. Finally, American International Group Inc. grew its position in shares of Esperion Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 584 shares during the period. 89.82% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Ameriprise Financial Inc. Sells 8,110 Shares of Esperion Therapeutics, Inc. (ESPR)” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/ameriprise-financial-inc-sells-8110-shares-of-esperion-therapeutics-inc-espr/1679748.html.

Esperion Therapeutics, Inc. (NASDAQ ESPR) opened at $47.62 on Friday. Esperion Therapeutics, Inc. has a one year low of $9.42 and a one year high of $57.40.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by ($0.25). During the same quarter last year, the company posted ($0.62) EPS. analysts expect that Esperion Therapeutics, Inc. will post -7.12 earnings per share for the current year.

A number of analysts have recently weighed in on ESPR shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $70.00 target price (up from $60.00) on shares of Esperion Therapeutics in a research report on Thursday, August 10th. Deutsche Bank AG set a $64.00 target price on shares of Esperion Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Jefferies Group LLC raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and reduced their target price for the stock from $85.00 to $55.00 in a research report on Tuesday, August 8th. BidaskClub downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 4th. Finally, Northland Securities reissued a “buy” rating and set a $72.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $58.92.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.